Table of Contents

November 2019 • Volume 18 • Issue 11

Highlights of This Issue 1897

REVIEWS

1899
ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications
Samantha A. Armstrong, Christopher W. Shultz, Ariana Azimi-Sadjadi, Jonathan R. Brody, and Michael J. Pishvaian

1909
Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance
Nabil F. Saba, Zhuo Gerogia Chen, Missak Haigentz, Paolo Bossi, Alessandra Rinaldo, Juan P. Rodrigo, Antti A. Mäkitie, Robert P. Takes, Primoz Strojan, Jan B. Vermorken, and Alfio Ferlito

SMALL MOLECULE THERAPEUTICS

1916
First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits ß-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer
Anna Capasso, Stacy M. Bagby, Kyrie L. Dailey, Naomi Currimjee, Betelehem W. Yacob, Anastasia Ionkina, Julie G. Frank, Deog Joong Kim, Christina George, Young B. Lee, Ely Benaim, Brian Gittleman, Sarah J. Hartman, Aik Choong Tan, Jihye Kim, Todd M. Pitts, S. Gail Eckhardt, John J. Tentler, and Jennifer R. Diamond

1926
Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Kerry A. Whalen, Brian H. White, James M. Quinn, Kristina Kriksciukaite, Rossitza Alargova, Tsun P. Au Yeung, Patrick Bazinet, Adam Brockman, Michelle M. DuPont, Haley Oller, James Gifford, Charles-Andre Lemelin, Patrick Lim Soo, Samantha Perino, Benoît Moreau, Gitanjali Sharma, Rajesh Shinde, Beata Sweryda-Krawiec, Mark T. Bilodeau, and Richard Wooster

1937
Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-Time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia

1947
Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer

1961
DHA-SBT-1214 Taxoid Nanoemulsion and Anti–PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model
Gulzar Ahmad, Gerardo G. Mackenzie, James Egan, and Mansoor M. Amiji

1973
The Novel Small-Molecule SR18662 Efficiently Inhibits the Growth of Colorectal Cancer In Vitro and In Vivo
Julie Kim, Chao Wang, Ainara Ruiz de Sabando, Hannah L. Cole, Timothy J. Huang, Jie Yang, Thomas D. Bannister, Vincent W. Yang, and Agnieszka B. Bialkowska

1985
KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors — TORC1/2 Inhibition as Salvage Strategy
Thomas Mühlenberg, Julia Ketzer, Michael C. Heinrich, Susanne Grunewald, Adrian Marino-Enriquez, Marcel Trautmann, Wolfgang Hartmann, Eva Wandelmann, Jürgen Treckmann, Karl Worm, Stefanie Bentram, Thomas Herold, Hans-Ulrich Schildhaus, Hanno Glimm, Albrecht Stenzinger, Benedikt Brors, Peter Horak, Peter Hohenberger, Stefan Fröhling, Jonathan A. Fletcher, and Sebastian Bauer

1997
Suppression of Prostate Cancer Pathogenesis Using an MDA-9/Syntenin (SDCBP) PDZ1 Small-Molecule Inhibitor
Swadesh K. Das, Timothy P. Kegelman, Anjan K. Pradhan, Xue-Ning Shen, Praveen Bhoopathi, Sarmistha Talukdar, Santanu Maji, Devanand Sarkar, Luni Emdad, and Paul B. Fisher
Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma

Siler H. Panowski, Tracy C. Kuo, Yi Zhang, Amy Chen, Tao Geng, Laura Aschenbrenner, Erin Kamperschroer, Edward Pascua, Wei Chen, Kathy DeLaria, Santiago Farías, Marjorie Bateman, Russell G. Dushin, Sherman M. Chin, Thomas J. Van Blarcom, Yik Andy Yeung, Kevin C. Lindquist, Allison G. Chunyk, Bing Kuang, Bora Han, Michael Mirsky, Ingrid Pardo, Bernard Buettow, Thomas G. Martin, Jeffrey L. Wolf, David Shelton, Arvind Rajpal, Pavlo Strop, Javier Chaparro-Riggers, and Barbra J. Sasu

Anti-miRNA Oligonucleotide Therapy for Chondrosarcoma

Xiaojuan Sun, Yupeng Chen, Hongchuan Yu, Jason T. Machan, Ashna Alladin, Jose Ramirez, Ross Taliano, Jesse Hart, Qian Chen, and Richard M. Terek

Development of Therapeutic Anti-JAGGED1 Antibodies for Cancer Therapy

Massimo Masiero, Demin Li, Pat Whiteman, Carol Bentley, Jenny Greig, Tasneem Hassanali, Sarah Watts, Stephen Stubbilng, Jenna Yates, Ellen Bealing, Ji-Liang Li, Chandramouli Chillakuri, Devon Sheppard, Sébastien Sannes, Manuel Sarmiento-Soto, James Larkin, Nicola R. Sibson, Penny A. Handford, Adrian L. Harris, and Alison H. Banham

U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer

Shigehiro Koganemaru, Yasutoshi Kuboki, Yoshikatsu Koga, Takashi Kojima, Mayumi Yamashita, Naoyuki Maeda, Takashi Kagari, Kenji Hirotani, Masahiro Yasunaga, Takashi Kojima, Mayumi Yamauchi, Naoyuki Maeda, Takashi Kagari, Kenji Hirotani, Masahiro Yasunaga, Yasuhiro Matsumura, and Toshihiko Doi

Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1dLAG3–Knockin Mice

Elena Burova, Ayhum Hermann, Jie Dai, Erica Ullman, Gabor Halasz, Terra Potocsky, Seongwom Hong, Matt Liu, Omaima Allbritton, Amy Woodruff, Jerry Pei, Ashique Rafique, William Poutemiyinou, Joel Martin, Douglas MacDonald, William C. Olson, Andrew Murphy, Ella Ioffe, Gavin Thurston, and Markus Mohrs

PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation

Anna R. Michmerhuizen, Andrea M. Pesch, Leah Moubadder, Benjamin C. Chandler, Karin Wilder-Romans, Meleah Cameron, Eric Olsen, Dafydd G. Thomas, Amanda Zhang, Nicole Hirsh, Cassandra L. Ritter, Meiian Liu, Shyam Nyati, Lori J. Pierce, Reshma Jagi, and Corey Speers

Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model

Jun Wang, Darren K.W. Chan, Arindam Sen, Wen Wee Ma, and Robert M. Straubinger

Glibenclamide Targets Sulfonylurea Receptor 1 to Inhibit p70S6K Activity and Upregulate KLF4 Expression to Suppress Non–Small Cell Lung Carcinoma

Kexin Xu, Geng Sun, Min Li, Hongling Chen, Zuhao Zhang, Xisi Qian, Ping Li, Lin Xu, Wenbin Huang, and Xuerong Wang

Target Deconvolution of a Multikinase Inhibitor with Antimetastatic Properties Identifies TAKO3 as a Key Contributor to a Cancer Stem Cell–Like Phenotype

Yansong Bian, Yaroslav Teper, Lesley A. Mathews Griner, Taylor J. Aiken, Vivek Shukla, Rajarshi Guha, Paul Shinn, Hong-Wu Xin, Holger Pflücker, Astin S. Powers, Dandan Li, Jian-kang Jiang, Paesuma Patel, Steven A. Rogers, Jeffrey Aubé, Marc Ferrer, Craig J. Thomas, and Udo Rudloff

COMMD3:BMI1 Fusion and COMMD3 Protein Regulate C-MYC Transcription: Novel Therapeutic Target for Metastatic Prostate Cancer

Syed Umbeeren, Mudassir Meraj Banday, Aamibreen Jamroz, Adrian P. Mansini, Ashbeer A. Ganaie, Marina G. Ferrari, Railhana Maqbool, Firdous H. Beigh, Paari Munugan, Colm Morrissey, Eva Corey, Badrinath R. Konety, and Mohammad Saleem

Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma

Marta Baro, Cecilia Lopez Sambrooks, Barbara A. Burtness, Mark A. Lemmon, and Joseph N. Contessa
HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer
Aïda Sampera, Francisco Javier Sánchez-Martín, Oriol Arpi, Laura Visa, Mar Iglesias, Silvia Menéndez, Élisabeth Gaye, Alba Dalmases, Sergi Clavé, Mariona Gelabert-Baldrish, Thomas Tuxen Poulsen, Michael Kragh, Beatriz Bellosillo, Joan Albanell, Ana Rovira, and Clara Montagut

Targeting PI3K/Akt/mTOR Pathway Identifies Differential Expression and Functional Role of IL8 in Liver Cancer Stem Cell Enrichment
Deniz Cansen Kahraman, Tamer Kahraman, and Rengul Cetin-Atalay

eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer

Improved Drug Delivery to Brain Metastases by Peptide-Mediated Permeabilization of the Blood–Brain Barrier
Synnøve Nymark Aasen, Heidi Espedal, Christopher Florian Holte, Olivier Keunen, Tine Veronika Karlsen, Olav Tenstad, Zaynah Maherally, Hrvoje Miletic, Tuyen Hoang, Anne Vaag Eikeland, Habib Baghirov, Dag Erlend Olberg, Geoffrey John Pilkington, Gobinda Sarkar, Robert B. Jenkins, Terje Sundstrøm, Rolf Bjerkvig, and Frits Thorsen

Correction: An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer

MODELS AND TECHNOLOGIES
ABOUT THE COVER

Desmoplasia, hypovascularity, and hypoperfusion work in tandem to prevent antibody therapy of pancreatic adenocarcinoma. In order to disrupt the tumor-stroma interaction and alleviate these factors, Wang and colleagues designed a smoothened inhibitor of sonic hedgehog signaling (NVP-LDE225). In the patient-derived xenograft shown on the cover, NVP-LDE225 reduced the number of Ki67+ tumor cells (shown in green). Cell nuclei are counterstained in blue. Taken together, their results demonstrate that NVP-LDE225 dosage for five to ten days primes tumors for treatment with therapeutic antibodies such as cetuximab. Their results rationalize future clinical study of NVP-LDE225 in solid tumors. Read the full article on page 2074.